Motor Function Measure Scale (MFM): New Instrument for Follow-Up Brazilian Patients with Neuromuscular Disease

OBJECTIVE: Evaluate muscle force and motor function in patients with Duchenne muscular dystrophy (DMD) in a period of six months. METHOD: Twenty children and adolescents with diagnosis of DMD were evaluated trough: measurement of the strength of the flexors and extensors of the shoulder, elbow, wrist, knee and ankle through the Medical Research Council (MRC), and application of the Motor Function Measure (MFM). The patients were evaluated twice within a six-month interval. RESULTS: Loss of muscle strength was identified in the MRC score for upper proximal members (t=-2.17, p=0.04). In the MFM, it was noted significant loss in the dimension 1 (t=-3.06, p=0.006). Moderate and strong correlations were found between the scores for muscular strength and the MFM dimensions. CONCLUSION: The MFM scale was a useful instrument in the follow up of patients with DMD. Moreover, it is a more comprehensive scale to assess patients and very good for conducting trials to evaluate treatment.

Download Full-text

Effect of Long-Term Repeated Interval Rehabilitation on the Gross Motor Function Measure in Children with Cerebral Palsy

Neuropediatrics ◽

10.1055/s-0040-1715489 ◽

2020 ◽

Vol 51 (06) ◽

pp. 407-416

Author(s):

Christina Stark ◽

Ibrahim Duran ◽

Kyriakos Martakis ◽

Karoline Spiess ◽

Oliver Semler ◽

...

Keyword(s):

Cerebral Palsy ◽

Motor Function ◽

Treatment Effect ◽

Standard Of Care ◽

Rehabilitation Program ◽

Additional Treatment ◽

Gross Motor ◽

Gross Motor Function Measure ◽

Function Measure

Abstract Background The efficacy of interventions for cerebral palsy (CP) has been frequently investigated with inconclusive results and motor function measured by the Gross Motor Function Measure (GMFM-66) is common. Objective In this observational analysis, we quantify the GMFM-66 change scores of the second and third year of a multimodal rehabilitation program (interval rehabilitation including home-based, vibration-assisted training) in children with CP. Methods The study was a retrospective analysis of children with CP (2–13 years) participating for a second (n = 262) and third year (n = 86) in the rehabilitation program with GMFM-66 scores at start (M0), after 4 months (M4) of intensive training, and after 8 months of follow-up (M12). A method was previously developed to differentiate between possible treatment effects and expected development under standard of care for GMFM-66 scores using Cohen's d effect size (ES; size of difference). Results After the treatment phase of 4 months (M4) in the second year, 125 of 262 children were responder (ES ≥ 0.2) and 137 children nonresponder (ES < 0.2); mean ES for nonresponder was −0.212 (trivial) and for responder 0.836 (large). After M4 in the third year, 43 children of 86 were responder (ES = 0.881 [large]) and 43 nonresponder (ES = −0.124 [trivial]). Discussion and Conclusion Repeated rehabilitation shows a large additional treatment effect to standard of care in 50% of children which is likely due to the intervention, because in the follow-up period (standard of care), no additional treatment effect was observed and the children followed their expected development.

Download Full-text

Motor function measure: Construction of a short form (MFM-20) for children with neuromuscular disease aged between 2 and 6

Annals of Physical and Rehabilitation Medicine ◽

10.1016/j.rehab.2011.07.449 ◽

2011 ◽

Vol 54 ◽

pp. e199-e200 ◽

Cited By ~ 1

Author(s):

C. De Lattre ◽

C. Payan ◽

C. Berard

Keyword(s):

Motor Function ◽

Neuromuscular Disease ◽

Short Form ◽

Function Measure

Download Full-text

Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using gross motor function measure

European Journal of Neurology ◽

10.1046/j.1468-1331.2001.00044.x ◽

2001 ◽

Vol 8 (s5) ◽

pp. 120-126 ◽

Cited By ~ 31

Author(s):

M. Linder ◽

G. Schindler ◽

U. Michaelis ◽

S. Stein ◽

J. Kirschner ◽

...

Keyword(s):

Cerebral Palsy ◽

Botulinum Toxin ◽

Motor Function ◽

Botulinum Toxin Type A ◽

Botulinum Toxin Type ◽

Medium Term ◽

Gross Motor Function Measure ◽

Children With Cerebral Palsy ◽

Function Measure

Download Full-text

M.P.2.02 Motor function measure: construction of a short form (MFM-20) for children with neuromuscular disease aged between 2 and 6

Neuromuscular Disorders ◽

10.1016/j.nmd.2009.06.090 ◽

2009 ◽

Vol 19 (8-9) ◽

pp. 571

Author(s):

C. de Lattre ◽

C. Payan ◽

C. Payet ◽

C. Fafin ◽

F. Girardot ◽

...

Keyword(s):

Motor Function ◽

Neuromuscular Disease ◽

Short Form ◽

Function Measure

Download Full-text

Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy

Arquivos de Neuro-Psiquiatria ◽

10.1590/s0004-282x2012000300007 ◽

2012 ◽

Vol 70 (3) ◽

pp. 191-195 ◽

Cited By ~ 10

Author(s):

Elaine C. da Silva ◽

Darlene L. Machado ◽

Maria B. D. Resende ◽

Renata F. Silva ◽

Edmar Zanoteli ◽

...

Keyword(s):

Duchenne Muscular Dystrophy ◽

Muscular Dystrophy ◽

Motor Function ◽

Motor Performance ◽

Three Dimensions ◽

Walking Ability ◽

Standing Posture ◽

Motor Functions ◽

Function Measure

OBJECTIVE: To assess the evolution of motor function in patients with Duchenne muscular dystrophy (DMD) treated with steroids (prednisolone or deflazacort) through the Motor Function Measure (MFM), which evaluates three dimensions of motor performance (D1, D2, D3). METHODS: Thirty-three patients with DMD (22 ambulant, 6 non-ambulant and 5 who lost the capacity to walk during the period of the study) were assessed using the MFM scale six times over a period of 18 months. RESULTS: All the motor functions remained stable for 14 months in all patients, except D1 for those who lost their walking ability. In ambulant patients, D2 (axial and proximal motor capacities) motor functions improved during six months; an improvement in D3 (distal motor capacity) was noted during the total follow-up. D1 (standing posture and transfers) and total score were useful to predict the loss of the ability to walk. CONCLUSIONS: The use of the MFM in DMD patients confirms the benefits of the steroid treatment for slowing the progression of the disease.

Download Full-text